MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke

MHRA review confirms benefit/risk profile of Alteplase - the only licensed clot buster for acute ischaemic stroke
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news